Following initial successes in melanoma treatment, immunotherapy has rapidly become
established as a major treatment modality for multiple types of solid cancers, including a …

Cancer is a multifactorial pathology and it represents the second leading cause of death
worldwide. In the recent years, numerous studies highlighted the dual role of the gut …

Background Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell
death 1 receptor. The combination of chemotherapy and immunotherapy may have …

PURPOSE Modulation of vascular endothelial growth factor–mediated immune suppression
via angiogenesis inhibition may augment the activity of immune checkpoint inhibitors. We …

ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma …

Background Lenvatinib is a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3, and
other receptor tyrosine kinases. Pembrolizumab, an antibody targeting PD-1, has moderate …

Colorectal cancer is the third most common cancer worldwide with a high mortality rate at
the advanced stages. However, colorectal cancer is not a single type of tumor; its …

Nonsense-mediated RNA decay (NMD) is a highly conserved RNA turnover pathway that
selectively degrades RNAs harbouring truncating mutations that prematurely terminate …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

Effective clinical cancer immunotherapies, such as administration of the cytokine IL-2,
adoptive cell transfer (ACT) and the recent success of blockade of the checkpoint …